We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

26 hedge funds and large institutions have $909K invested in Titan Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

4% more funds holding

Funds holding: 25 → 26 (+1)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

3% less capital invested

Capital invested by funds: $939K → $909K (-$29.9K)

Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
4
Closed
4
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
+$4K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$545K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$76.2K
3
VF
Virtu Financial
New York
+$62.8K
4
Citadel Advisors
Citadel Advisors
Florida
+$25.8K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$23.5K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$314K
2
PCM
Perkins Capital Management
Minnesota
-$204K
3
Renaissance Technologies
Renaissance Technologies
New York
-$139K
4
AC
Armistice Capital
New York
-$46K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$1.12K

TTNP Hedge Fund Activity: Q4 2018 in Review

26 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2018, worth a combined $909K — down 3.2% from $939K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TTNP positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $545K. The largest seller was Sabby Management, exiting entirely with an estimated $314K sold.

  • 26 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2018, up from 25 in Q3 2018.
  • Funds reported $909K of Titan Pharmaceuticals stock for Q4 2018, down 3.2% quarter-over-quarter.
  • 5 funds opened new Titan Pharmaceuticals positions in Q4 2018 and 4 closed out, a net change of +1 holder.
  • The largest Titan Pharmaceuticals buyer in Q4 2018 was Vanguard Group, an estimated $545K added.
  • The largest Titan Pharmaceuticals seller in Q4 2018 was Sabby Management, an estimated $314K sold.

Based on aggregated 13F filings for Q4 2018.